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Brian Godman – research activities
▪ PhD research activities (starting in 2006) initially in 7 EU 
countries to:
❑ Increase the prescribing of generics first line and drive 
down their prices to enhance prescribing efficiency
❑ Optimise reimbursement/ funding decisions for new 
medicines and their subsequent utilisation leading to the 
development of new models starting pre-launch
▪ Research interests subsequently extended globally and include 
activities to improve the quality and efficiency of prescribing/ 
dispensing of new and established medicines across multiple 
disease areas/ product classes including infectious and NCDs. 
This includes biosimilars
▪ Co-Founder of Piperska (Europe - 2008) and MURIA (2015)
▪ Over 350 peer reviewed publications in the past 15 years with 
payers/ advisers/ academics across multiple continents/ 
countries including Asia – with most listed in Pub Med
▪ Several publications involving Korea (solely or part of multi-
country publications)
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▪Global expenditure on medicines will soon reach 
US$1.5trillion, with medicines for chronic, complex, or rare 
diseases such as cancer and orphan diseases, accounting for 
over 50% and growing with increasing prices for new 
medicines 
▪These growth rates are unsustainable alongside the need to 
fund increased volume of medicines for patients with chronic 
non-communicable diseases with ageing populations alongside 
new high priced medicines to treat areas of unmet need
▪In addition, patients in an appreciable number of countries do 
not have access to biologicals including anti-TNFs for RA and 
IBD as well as trastuzumab/ rituximab for oncology due to 
their high costs/ high patient co-payments
▪Biosimilars offer a way forward, e.g. adalimumab was the top 
selling medicine in Germany in 2017 and the anti-TNFs were 
one of the top selling medicines in the UK in 2018
The potential role of biosimilars will increase 
with growing expenditure on biologicals
Ref: Inoati et al 2017; Moorkens et al 2017, Godman et al 2018, 2019, and accepted
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The cost of cancer medicines now averages US$207,000/ life year 
gained (2013$) – This is likely to be an underestimate as modelling 
and concerns between linking PFS (typical outcome measure) and 
overall survival (needed for LYG calculations) in solid tumours 
Ref: Howard et al 2015; Godman et al 2015, 2018
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Concerns with ever increasing prices for new medicines 
for orphan diseases aided by the emotive nature of the 
disease area is resulting in publications such as Luzzatto 
et al in the Lancet in 2018, and limiting access to patients 
with orphan diseases across countries. Biosimilars may 
eventually help
Re: Luzzatto et al 2018
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There has been variable 
use of biological 
medicines to treat 
patients with rheumatoid 
arthritis across Europe in 
recent years
Putrik at al in 2014 
showed considerable 
variation depending on 
issues of socioeconomic 
status, co-payments and 
disease severity
High scores were 
associated with good 
access 
Ref: Putrik et al 2014
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There is also 
considerable 
variation in the 
use of biologicals 
in patients with 
inflammatory 
bowel disease 
across Europe 
driven again by 
issues of access 
and affordability
Kostic et al in 
Serbia also found 
limited use of 
biologicals for 
IBD due to high 
patient co-
payments 
Ref: Kostic et al 2017; Baumgart et al 2019
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▪Humira had global sales of US$19.9 billion in 2018; with 
rituximab, infliximab, and etanercept having global sales of 
US$7.9billion, US$ 5.9 billion and US$ 5.8 billion in 2017 
respectively – all now reducing with biosimilars launched
▪Global sales of trastuzumab were stable in 2019 at US$7billion 
due to increasing use of biosimilars with biosimilars already 
capturing 45% of the European market and growing  
▪The insulin glargine market was valued at US$3.88 billion in 
2018 envisaged to reach US$9.26 billion by 2025 with growing 
rates of diabetes worldwide. Biosimilars can help here as well
▪Can be considerable savings with biosimilars without affecting 
care, especially with more biosimilars becoming available, e.g. 
expenditure on adalimumab in the UK was estimated to fall by 
75% following the availability of biosimilars and among Danish 
hospitals, expenditures decreased by 82.8% following 
biosimilars with almost total replacement (95.1% utilisation)
There is potential for appreciable savings with 
biosimilars given high sales of biologicals
Ref: Godman et al 2019, and accepted, Jensen et al 2020
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There were considerable savings for 
adalimumab among Danish hospitals following 
biosimilars with almost total use of low cost 
biosimilars (82.8% reduction in expenditure) 
Ref: Jensen et al 2020
Red line indicates when biosimilars became available
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There have been concerns with the 
effectiveness and safety of biosimilars –
addressed by studies such as NOR-SWITCH 
study sponsored by the Norwegian Government 
….
Ref: Jorgensen et al 2017
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… as well as growing realization that originator 
companies often change their manufacturing 
process without having to undertake further 
studies – so in effect biosimilars as well
Ref: Jimenez-Pichardo et al 2018, Godman et al 2019
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▪However – there can be occasions where savings are more 
limited with biosimilars as currently seen with insulin glargine 
across countries with limited price reductions and concerns 
with switching with different pens and familiarity
▪Typically, both supply- and demand side-measures are needed 
to maximise savings from biosimilars
▪Supply-side measures include encouraging competition 
through tenders, e.g. Danish Hospitals and UK with 
adalimumab
▪Demand-side measures include education, engineering, 
economics and enforcement (4Es)
▪Without both – limited savings. In fact in Korea – when 
biosimilar infliximab introduced there was limited use of the 
biosimilar alongside appreciably increased use of the 
originator – NOT the desired aim
There can be concerns with some biosimilars. 
Both demand and supply side measures needed
Ref: Wettermark et al, 2009, Godman et al 2019 and accepted; Kim et al 2020
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This was our recently published study involving 
Korea – available Open Access
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▪Education – includes education of all key stakeholder groups 
including physicians, pharmacists and patients – especially 
with concerns with the nocebo effect. An increasing number of 
published studies showing no difference in the effectiveness 
and safety between originators and biosimilars should help 
here
▪ Engineering – includes setting goals for % of patients started 
on biosimilars as well as switching (where pertinent). In 
addition, benchmarking of physicians among each other for 
biosimilar prescribing rates and potential savings
▪Economics – financial benefits for patients (e.g. lower 
premiums and co-pays) and physicians (directly as well as 
indirectly) from increasing use of biosimilars. In addition –
sanctions including removing of licences
▪Enforcement – compulsory INN prescribing; compulsory 
substitution 
Demand-side measures can be collated under 
the 4Es and include education and economics
Ref: Moorkens et al 2017, Godman et al 2019 and accepted; Dutta et al 2020
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The potential nocebo effect with biosimilars is 
discussed in this and other papers
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Potential demand-side policies in other 
countries are discussed in this publication 
(Europe) and others
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Potential demand-side measures across 
countries is also discussed in this paper
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Other potential advantages from increasing 
use of biosimilars – apart from increasing 
access to therapy and physician numbers to 
treat more patients – include simulating 
research into the next generation of 
biologicals through making savings available 
to fund them
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▪In conclusion, biosimilars offer considerable advantages to 
healthcare systems struggling to cope with increasing 
demands – made worse by the current COVID-19 pandemic. 
In addition help patients where high co-payments
▪However both appropriate supply- and demand-side measures 
are necessary to fully realise the potential of biosimilars. This 
is important especially if originator companies are looking to 
aggressively lower prices to stave off competition (e.g. AbbVie 
with HUMIRA in the Netherlands)
▪Savings will grow as more biosimilars become available across 
disease areas especially in oncology
▪In time – may well see re-evaluation of the prices of existing 
patented medicines that used a biological medicine that has 
now become available as a biosimilar for referencing in 
negotiations. This becomes important with some of the 
considerable price reductions seen with biosimilars (80 – 90%)
Biosimilars are increasingly necessary. Both 
demand- and supply-side measures important 
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Thank You
Any Questions!
Brian.godman@strath.ac.uk; 
briangodman@outlook.com
